Results 221 to 230 of about 3,217,560 (288)
Mapping political commitments: Analysing health priorities in Indian election manifestos. [PDF]
Rajeev BR, Ram A, Nivedhya R, Das SS.
europepmc +1 more source
Abstract Aims In the context of pharmacology and toxicology education, there is a growing shift toward programmatic assessment models that prioritize longitudinal learning, reflection and development of higher‐order cognitive skills. As part of this transition, we are exploring alternative and more meaningful forms of assessment. This qualitative study
Narin Akrawi +2 more
wiley +1 more source
Autonomy and refusal of dialysis: ethical and legal reflections based on the position statement of the Brazilian Society of Nephrology. [PDF]
Santos CGDS, Guirro ÚBDP, Dadalto L.
europepmc +1 more source
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Third-Party Access Cybersecurity Threats and Precautions: A Survey of Healthcare Delivery Organizations. [PDF]
Gellert GA +4 more
europepmc +1 more source
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
Association of SP Educators (ASPE) Physical Examination Teaching Associate (PETA) Standards of Best Practice (SOBP). [PDF]
Hopkins H +4 more
europepmc +1 more source
Low‐intervention clinical trials in Spain: Do they progress?
Abstract Aims Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory ...
Claudia Erika Delgado‐Espinoza +4 more
wiley +1 more source

